There is no Significant Association Between Death Receptor 4 (DR4) Gene Polymorphisms and Lung Cancer in Turkish Population

[1]  W. Xu,et al.  TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. , 2009, European journal of cancer.

[2]  P. Devilee,et al.  Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. , 2009, Cancer letters.

[3]  Meilin Wang,et al.  Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer. , 2009, Mutation research.

[4]  L. Chun.  Association of DR4 Gene Polymorphism in Chinese Patients with Gastroduodenal Diseases , 2007 .

[5]  J. Benítez,et al.  Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. , 2007, Cancer biomarkers : section A of Disease markers.

[6]  H. Brenner,et al.  Death Receptor 4 Variants and Colorectal Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[7]  H. Döhner,et al.  Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer , 2006, International journal of cancer.

[8]  R. Zeillinger,et al.  Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. , 2005, Gynecologic oncology.

[9]  K. Debatin,et al.  Mutation analysis of the apoptotic “death‐receptors” and the adaptors TRADD and FADD/MORT‐1 in osteosarcoma tumor samples and osteosarcoma cell lines , 2004, International journal of cancer.

[10]  E. Campo,et al.  Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. , 2004, Haematologica.

[11]  M. Spitz,et al.  Death receptor 4 and bladder cancer risk. , 2003, Cancer research.

[12]  P. Schlag,et al.  Mutation analysis and mRNA expression of trail‐receptors in human breast cancer , 2002, International journal of cancer.

[13]  T. Rebbeck,et al.  Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  M. Shin,et al.  Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma , 2001, Oncogene.

[15]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[16]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.